GlassScriptPhysician profile
John Vincent Cugini
NPI 1326501636
$1,787.57
in general payments reported to CMS, 2019-2025
25 companies · $1,081 in 2025
The $1,081 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $706 · 2025: $1,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,787.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $358.80 | 2024-2025 | |
| Lilly USA, LLC | $210.61 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $123.55 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $117.49 | 2024-2025 | Breztri, Farxiga |
| Novo Nordisk INC | $98.70 | 2024-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $90.22 | 2024-2025 | Trelegy Ellipta, Shingrix |
| Astellas Pharma US INC | $81.32 | 2024-2025 | Veozah |
| Abbott Laboratories | $78.08 | 2024-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $74.06 | 2025 | |
| Neurocrine Biosciences, INC. | $68.68 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.63 | 2024-2025 | Jardiance |
| Azurity Pharmaceuticals, INC. | $40.86 | 2024 | Horizant |
| Eisai INC. | $37.84 | 2025 | |
| Shield Therapeutics INC | $37.80 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $37.06 | 2025 | Rexulti |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $35.85 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Teva Pharmaceuticals USA, INC. | $34.94 | 2024-2025 | Austedo Xr, Austedo Xr |
| Seqirus USA INC | $32.89 | 2025 | Flucelvax, Fluad |
| Dexcom, INC. | $32.24 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $29.32 | 2025 | Cologuard Collection Kit |
| Ucb, INC. | $24.44 | 2025 | Nayzilam |
| Boston Scientific Corporation | $23.32 | 2025 | Wavewriter Alpha Prime 16 |
| Corium, LLC | $19.99 | 2024 | Azstarys |
| Bausch Health US, LLC | $19.54 | 2024 | Aplenzin |
| Kowa Pharmaceuticals America, INC. | $15.34 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cugini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.